In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AVEO Pharmaceuticals, Inc.

http://www.aveooncology.com/

Latest From AVEO Pharmaceuticals, Inc.

Time To Simplify US FDA’s Expedited Pathways? It Won’t Be Simple

Oncology center director Pazdur thinks it is time to streamline the expedited pathways for drug development in the US. Focusing on the goals, rather than the paperwork, is a good idea – but is easier said than done.

Drug Approval Standards Drug Review

US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Approvals Review Pathway

Tivozanib’s Efficacy Behind Checkpoint Inhibitors In Renal Cell Carcinoma Reassured US FDA

Approximately 25% of patients in the TIVO-3 trial had prior treatment with checkpoint inhibitors, but progression-free survival in this subgroup was similar to the overall population, giving the FDA confidence about tivozanib's role in contemporary treatment regimens, Drug Review Profile finds.

Drug Review Profile Cancer

AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis

After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.

Drug Review Profile Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • AVEO Oncology
UsernamePublicRestriction

Register